Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
about
Translational challenges of animal models in Chagas disease drug development: a reviewNovel amidines and analogues as promising agents against intracellular parasites: a systematic reviewSqualene synthase as a target for Chagas disease therapeutics4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo PotencyCombined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivoDiverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell deathAutomated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell lineSterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasisSQ109, a new drug lead for Chagas disease.Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' diseaseSuccessful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hostsA class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents.Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibitionDrug strategies targeting CYP51 in neglected tropical diseasesSuccessful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole.In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.Genome profiling of sterol synthesis shows convergent evolution in parasites and guides chemotherapeutic attack.In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi.The Anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazoleLimited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.Potent In Vitro Antiproliferative Synergism of Combinations of Ergosterol Biosynthesis Inhibitors against Leishmania amazonensis.Quinuclidine derivatives as potential antiparasiticsTargeting Trypanosoma cruzi sterol 14α-demethylase (CYP51)Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis.Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation.Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs.Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.Assessing anti-T. cruzi candidates in vitro for sterile cidality.In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruziIn vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile.Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease.Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.Experimental and Clinical Treatment of Chagas Disease: A Review.Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.
P2860
Q26796451-267F5F17-4E7D-4B8D-840A-BCC9583FA2D8Q26825025-561FED98-2EC2-4468-8B56-4CC1043078AAQ27683611-E3BD2DCC-9860-4A4C-9328-C1068672F1D1Q27684956-E24E4323-6219-4512-B69C-74920667EE3BQ28479294-4AD2463A-B087-4F8B-8C05-A4CA478CBF9AQ28481694-E68DBBFB-FDCA-4701-BF01-15E79BE89416Q28485411-B87D8906-D6D3-455D-AF2F-2B70E12127FEQ28543069-AD8EA06C-FA83-4CA7-A0E9-ADD7B1035218Q28727454-7AE0C5CD-3DDB-41B2-B599-01B9156D8063Q30626912-B18089CC-11AC-42B2-944B-0612433C2498Q33722151-E0A7BA5E-80A4-4A46-B728-4B819EA7AD24Q33749707-33E7BD87-1487-473F-A49C-A59662499A85Q33876638-9E384A64-129A-45B7-B137-2A3460AC6323Q33978515-394603BF-A9FE-4A1A-97EB-0DDCEE66DFA2Q34391586-BE2699E3-460B-45B3-BCD3-13F3B85254DFQ34614864-60E64405-0481-47E5-AEB7-C4A8F8112848Q34622554-71198C53-2BE9-46CD-BB6C-CDA083E22B17Q34737833-DC937084-21CB-4C89-A05C-2C45EF8F4324Q35077994-396BE739-F3BD-4731-8547-78230570E96DQ35120349-7C7BD73F-B9AB-406D-8145-0F3EB909CB9EQ35125554-2FDACEF8-EB2D-4DFF-9695-0BBCD03FF83BQ35758872-EFFD3886-3881-4323-A0AA-2BCD396B6CBFQ35859935-F8748F54-0892-4AC4-B95E-15F5F90E32C0Q36075944-91ECAE9F-C96B-4899-9F46-B6B3545BD075Q36295451-E069330C-C558-4D1D-A3B7-36EEFDD0F1DBQ36368984-A0EC38B9-B66C-4654-829A-D0B140457FE7Q36670149-953D4C31-5A15-4FC4-8F39-054003003881Q37254812-190A86B7-2D89-4D28-9D63-9AD536C61E07Q37579675-7F9C5AE8-ECB0-4AD2-A3B5-B3B0E4E0D09FQ37732551-1E008951-1176-4257-9A05-323D72ECE812Q38929035-2F4ECBBF-5DC4-4680-8EDF-9D4ABCFF1B37Q39474980-1454CE5E-4856-45A3-8C2F-CBFAA7157142Q39628520-B94A9322-C714-46B5-9814-B0348D160856Q39755589-B572F8FB-22E7-418F-B611-2B5C535F0330Q40290159-5B30C54E-64AD-4AB8-B511-C7716883BFB6Q41073713-EEDC1D9B-B986-4B8D-A198-E63A7F377D68Q41955446-C80A58ED-A09A-4CF6-B4BC-B25B73F595D2Q41989175-DBC059E0-5188-43AA-B09F-0326DF926484Q43215508-1345B444-EF23-4361-B9B9-8736184F79BD
P2860
Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Antiproliferative effects and ...... in vitro and in vivo studies.
@ast
Antiproliferative effects and ...... in vitro and in vivo studies.
@en
type
label
Antiproliferative effects and ...... in vitro and in vivo studies.
@ast
Antiproliferative effects and ...... in vitro and in vivo studies.
@en
prefLabel
Antiproliferative effects and ...... in vitro and in vivo studies.
@ast
Antiproliferative effects and ...... in vitro and in vivo studies.
@en
P2093
P2860
P356
P1476
Antiproliferative effects and ...... : in vitro and in vivo studies
@en
P2093
D Loebenberg
J A Urbina
P2860
P304
P356
10.1128/AAC.42.7.1771
P407
P577
1998-07-01T00:00:00Z